FDA approves new pancreatic cancer drug that could extend patients' lives
Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cbsnews.com — the content belongs to CBS News.
